The Promise of Peptides: What’s Approved, What’s Coming, and What to Wait On

Some links in this article are affiliate links; buying through them costs you nothing and supports the curation. How I choose.

Regulatory status as of October 2026. I will update this piece when the FDA acts.

I have spent forty years watching wellness fashions arrive with a great deal of noise. Peptides are the loudest I have seen in a while. Lately I am asked about them everywhere: in retreats, at dinner, in messages from women who have already ordered a vial online and want to know if they should be worried.

Often, they should be. Not because peptides are inherently dangerous, but because the word now covers everything from a well-studied prescription medicine to a powder shipped with a “not for human consumption” label. Those are not the same thing, and the difference matters most for women in our second chapter, who are being marketed to more aggressively than anyone.

So let me give you the map.

What a peptide actually is

A peptide is a short chain of amino acids, the same building blocks as protein, only smaller. Your body runs on them. Insulin is a peptide. So is oxytocin. One of them, a copper-binding tripeptide called GHK, circulates in human blood at levels that average about 200 ng/ml at age 20 and fall to about 80 ng/ml by age 60 (Dou et al., 2020).

Our grandmothers’ bone broths were, chemically, peptide sources long before anyone used the word. I find that continuity beautiful. It is not proof of anything, but it reminds me that the body has always known this language.

Peptides are not a trend. They are the body’s own grammar. What is new is how carelessly that grammar is being sold.

Why the rules matter: the regulatory story in plain English

There are four very different lanes, and most marketing blurs them:

1. FDA-approved peptide drugs. Prescribed by a licensed clinician, made to a verified standard. Semaglutide and tirzepatide are the famous examples.
2. Compounded peptides. Made by a pharmacy for an individual patient. Only allowed when the ingredient meets specific legal criteria.
3. Cosmetics and supplements. Topical copper peptides and oral collagen live here. They can make appearance or structure/function claims, not disease claims.
4. “Research use only” chemicals. Sold online, often with dosing calculators. These are not legal for human use.

What happened in 2026

• April 15, 2026. The FDA announced it would remove 12 peptides, including BPC-157, from its Category 2 list of substances that raise “significant safety risks” in compounding. The removal happened because the nominators withdrew their nominations. It was not a safety finding, and it did not make these peptides lawful to compound (Orrick, 2026; Frier Levitt, 2026).
• July 23–24, 2026. The FDA’s Pharmacy Compounding Advisory Committee narrowly recommended six peptides (BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon) for the list that would let pharmacies compound them. BPC-157 passed 8–6 with one abstention. FDA’s own staff had recommended against all of them, and the panel rejected a seventh, DSIP (STAT, 2026; AJMC, 2026).
• August 24, 2026. The FDA sent warning letters to five online sellers that marketed peptides as “research use only,” finding that their dosing instructions showed the products were intended for people (Arent Fox Schiff, 2026).
• As of October 2026, the FDA has not published a proposed or final rule adding any of these peptides to the compounding list. Advisory votes are nonbinding. A pharmacy compounding BPC-157 today is in the same legal position it was in before the vote (Buchanan Ingersoll & Rooney, 2026).

An advisory vote is a conversation, not a permission slip.

Skin: where peptides have earned a place

This is the most evidence-friendly territory, and it is where I am comfortable recommending products.

Oral collagen peptides

A 2021 systematic review and meta-analysis pooled 19 randomized, controlled trials covering 1,125 participants, 95% of them women. Hydrolyzed collagen supplementation improved skin hydration, elasticity and wrinkles compared with placebo (de Miranda et al., 2021). An earlier double-blind trial in 69 women aged 35 to 55 found that 2.5 g or 5 g of specific collagen peptides daily for eight weeks improved skin elasticity compared with placebo (Proksch et al., 2014).

The honest note: many of these trials are industry-funded, and results come from specific formulations. Think of collagen as a daily support for the skin’s own structure, not a transformation in a jar.

Topical copper peptides (GHK-Cu)

GHK-Cu has decades of laboratory work behind it. In cell and gene-expression studies it is associated with increased collagen, elastin and glycosaminoglycan synthesis and supports the function of dermal fibroblasts (Pickart & Margolina, 2018). Human data on finished skincare products is smaller and often run by manufacturers.

There is one more honest caveat. GHK-Cu is fairly water-loving, and the outer layer of skin is not. How well it penetrates, and how much formulation helps, is still an open research question (Ogórek et al., 2025). Use it as a quiet, consistent evening step and judge the look of your skin over three months, not three days.

A formulation note many skincare chemists follow: apply copper peptides in a different step from strong acids and high-strength vitamin C.

Wait on: injectable GHK-Cu. The FDA has deferred it to an advisory committee meeting before the end of February 2027 (Orrick, 2026).

Recovery: the BPC-157 phenomenon

If you follow anyone in the biohacking world, you have heard BPC-157 described as a miracle for tendons and joints. Here is what the evidence actually says.

A 2026 scoping review from UCLA’s orthopaedic surgery department examined six popular “recovery” peptides, including BPC-157 and TB-500. Two-thirds of the publications were animal studies. Human studies were few and mostly lacked robust controls. The authors concluded that the claimed benefits for musculoskeletal recovery “remain unsubstantiated by current human trials” (Tewari et al., 2026). A separate 2026 pharmaceutical review notes that BPC-157 has no approved formulation, no validated dosing regimen and no completed Phase II clinical trial (Mateescu et al., 2026).

Clinicians are also documenting the risks of gray-market injectables: contamination, manufacturing impurities and inaccurate dosing (Moiz et al., 2026).

Status: wait. I will not link to anywhere that sells these, and I would gently ask you not to buy them. The body holds the work, and it deserves better than an unlabeled vial.

What does support recovery in midlife is unglamorous and well studied: progressive strength training, adequate protein and protected sleep. (See our companion piece on creatine, which has far stronger human data than any recovery peptide.)

Fascinating biology in a rat is not a reason to inject yourself. It is a reason to wait for the trial.

Metabolism: where peptides are proven

This is the paradox of the moment. The best-studied peptide drugs in the world are metabolic ones. In the STEP 1 trial, once-weekly semaglutide produced substantially greater weight reduction than placebo in adults with overweight or obesity over 68 weeks (Wilding et al., 2021).

These are prescription medicines, with real side effects, and they belong in a conversation with a licensed clinician. If you explore them through telehealth, look for:

• a licensed prescriber who reviews your history,
• the FDA-approved, branded product or a named, licensed pharmacy,
• no language like “generic Ozempic” or “same as Wegovy” for a compounded product. That exact claim has drawn FDA warning letters to telehealth companies (Pharmaceutical Commerce, 2026).

Pair any such medicine with resistance training and protein. Muscle is the organ of independence in our later decades.

Desire: one approved peptide, with a caveat

Bremelanotide (Vyleesi) is FDA-approved for low sexual desire. In two phase 3 trials with 1,267 women, it improved desire and reduced related distress compared with placebo (Kingsberg et al., 2019). Those trials enrolled premenopausal women only, so its use after menopause is not established. Ask your clinician.

Longevity: MOTS-c, Epitalon and the rest

These were among the six the advisory panel backed. The biology is intriguing; the human data is minimal. Status: wait.

The Trove peptide literacy checklist

A closing thought

The oldest traditions I have studied all prized patience with powerful substances. Plant medicine taught me that the most potent things ask for the most respect. Modern science, at its best, asks the same of us: know what it is, know where it came from, know what the evidence says.

Choose the tools that have earned your trust. Let the rest earn it first.

The body holds the work. These are the tools that hold the body.

— Gillian

THE TROVE

Free · one issue a month · no filler

Read The Trove first.

Subscribe free and get The Honest Grades: 12 wellness trends, each graded Established, Promising or Wait. Then one issue a month, the research read honestly, before it goes public.

No spam. Unsubscribe anytime. How we treat your inbox · Privacy Policy · Terms.